Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > REGULATORY
REGULATORY
- MHLW to Implement Steps to Curb Social Security Spending as Needed: New Top Bureaucrat
October 26, 2015
- MHLW Asks Chuikyo to Revise Evaluation for Antipsychotic Therapies in Large Dosages without Adequate Guidance
October 26, 2015
- MHLW Lifts Request for Kaketsuken to Suspend Flu Vaccine Shipment
October 23, 2015
- Chuikyo OKs Expansion of Health Coverage for Investigator-Led Trials
October 22, 2015
- Impact of Z2 Rule to Be Discussed toward FY2016 Reform: MHLW
October 22, 2015
- New MHLW Economic Affairs Chief Visits Logistics Center, Says Distribution Key to Brightening Pharma Sector
October 22, 2015
- MHLW Likely to Announce 5 or So Sakigake Products Next Week
October 22, 2015
- Add Interstitial Pneumonia to Daklinza, Sunvepra Labels: MHLW
October 21, 2015
- MHLW to Show Detailed Steps to Foster Pharma Sector in November
October 21, 2015
- Patent Extension, Patent Linkage Rules in TPP Require No Rule Changes in Japan: MHLW Official
October 20, 2015
- 5 Members to Leave Chuikyo before Full-Fledged Debate Begins for 2016 Reform
October 20, 2015
- Govt to Reduce Stockpiles of Anti-Pandemic Flu Drugs
October 19, 2015
- PAFSC 1st Committee to Discuss Lexapro for Social Anxiety Disorder on Oct. 30
October 19, 2015
- AMED to Launch Project to Fund Orphan Drug Hopefuls
October 19, 2015
- AMED’s Joint Drug Discovery Project to See Match-Ups by the End of October: President Suematsu
October 16, 2015
- Chuikyo Subcommittee OKs 70% Threshold for DPC Incentive
October 16, 2015
- Additional Indication of Xeloda, Elplat to Be Reported to PAFSC’s 2nd Committee on Oct. 29
October 16, 2015
- High Unmet Medical Need for Lenalidomide: Council on Unapproved Drugs
October 16, 2015
- MHLW Council on Unapproved Drugs to Review Appropriateness of Humanitarian Trials, Notification Due Out November
October 15, 2015
- Chuikyo Subcommittee Roughly OKs Sakigake Pricing Premium, Yet No Agreement on Rate Raise
October 15, 2015
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…